Timed 25-Foot Walk: Direct evidence that improving 20% or greater is clinically meaningful in MS

Neurology

Volumn 80, Issue 16, 2013, Pages 1509-1517

  Hobart, Jeremy ^a   Blight, Andrew R ^b   Goodman, Andrew ^c   Lynn, Frances ^d   Putzki, Norman ^e  

^a UNIVERSITY OF PLYMOUTH   (United Kingdom)

^b ACORDA THERAPEUTICS INC   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d Medical Research   (United Kingdom)

^e Biogen Idec International GmbH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; POTASSIUM CHANNEL BLOCKING AGENT;

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SELF REPORT; TIMED 25 FOOT WALK; TREATMENT RESPONSE; WALKING SPEED; AGED; GAIT; META ANALYSIS; META ANALYSIS (TOPIC); METHODOLOGY; MIDDLE AGED; NEUROLOGIC EXAMINATION; NEUROLOGIC GAIT DISORDER; PHYSIOLOGY; REPRODUCIBILITY; REVIEW; WALKING;

4-AMINOPYRIDINE; ADULT; AGED; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; GAIT; GAIT DISORDERS, NEUROLOGIC; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; POTASSIUM CHANNEL BLOCKERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; WALKING;

MLCS; MLOWN;

EID: 84878758881     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31828cf7f3     Document Type: Article

References (38)

1. Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? QJM 2004;97:671-676.
2. Kesselring J. Disease progression in multiple sclerosis I. Impaired mobility and its impact on limitations of activities and social participation. Eur Neurol Rev 2010;5:56-60.
3. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10-relapses and long-term disability. Brain 2010;133:1914-1929.
4. Dunn J. Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res 2010;10:433-440.
5. Sutliff MH. Contribution of impaired mobility to patient burden in multiple sclerosis. Curr Med Res Opin 2010;26:109-119.
6. Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther 2009;26:1043-1057.
7. Martin CL, Phillips BA, Kilpatrick TJ, et al. Gait and balance impairment in early multiple sclerosis in the absence of clinical disability. Mult Scler 2006;12:620-628.
8. Heesen C, Bohm J, Reich C, Kasper J, Goebel M, Gold SM. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler 2008;14:988-991.
9. Kieseier BC, Pozzilli C. Assessing walking disability in multiple sclerosis. Mult Scler 2012;18:914-924.
10. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999;5:244-250.
11. Cohen JA, Fischer JS, Bolibrush DM, et al. Intrarater and interrater reliability of the MS Functional Composite outcome measure. Neurology 2000;54:802-806.
12. Kaufman M, Moyer D, Norton J. The significant change for the Timed 25-Foot Walk in the Multiple Sclerosis Functional Composite. Mult Scler 2000;6:286-290.
13. Schwid SR, Goodman AD, McDermott MP, Bever CF, Cook SD. Quantitative functional measures in MS: what is a reliable change? Neurology 2002;58:1294-1296.
14. Hoogervorst EL, Kalkers NF, Cutter GR. Uitdehaag BM, Polman CH. The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite. Mult Scler 2004;10:55-60.
15. Kragt JJ, Van der Linden FA, Nielsen JM, Uitdehaag BM, Polman CH. Clinical impact of 20% worsening on Timed 25-Foot Walk and 9-Hole Peg Test in multiple sclerosis. Mult Scler 2006;12:594-598.
16. Polman CH, Rudick RA. The Multiple Sclerosis Functional Composite: a clinically meaningful measure of disability. Neurology 2010;74(suppl 3):S8-S15.
17. Costelloe L, Hutchinson M. Is a 20% change in MSFC components clinically meaningful? Mult Scler 2007;13:1076.
18. Sharrack B, Hughes RA. The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler 1999;5:223-233.
19. Food and Drug Administration. Patient reported outcome measures: use in medical product development to support labeling claims. US Department of Health and Human Services, 2009. Available at: http://www.fda. gov/downloads/Drugs/ GuidanceCompliance-RegulatoryInformation/Guidances/UCM193282.pdf. Accessed December 2009.
20. Goodman AD, Brown TR, Krupp LB, et al. Sustainedrelease oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373:732-738.
21. Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010;68:494-502.
22. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 2003;60:31-36.
23. Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter G. Multiple Sclerosis Functional Composite (MSFC) Administration and Scoring Manual (revised 2001 edition) [online]. Available at: http://www.nationalmssociety.org/for- professionals/researchers/clinical-study-measures/msfc/download. aspx? id=259. Accessed October 26, 2012.
24. McGuigan C, Hutchinson M. Confirming the validity and responsiveness of the Multiple Sclerosis Walking Scale-12 (MSWS-12). Neurology 2004;62:2103-2105.
25. Motl RW, Snook EM. Confirmation and extension of the validity of the Multiple Sclerosis Walking Scale-12 (MSWS-12). J Neurol Sci 2008;268:69-73.
26. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999;37:469-478.
27. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999;52:861-873.
28. Anastasi A, Urbina S. Psychological Testing, 7th ed. Upper Saddle River, NJ: Prentice Hall; 1997.
29. Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 2002;55:285-295.
30. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547-561.
31. Eton DT, Cella D, Yost KJ, et al. A combination of distribution-and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004;57:898-910.
32. Yost KJ, Cella D, Chawla A, et al. Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution-and anchor-based approaches. J Clin Epidemiol 2005;58:1241-1251.
33. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-121.
34. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297-334.
35. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Academic Press; 1969.
36. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27:S178-S189.
37. Katz JN, Larson MG, Phillips CB, Fossel AH, Liang MH. Comparative measurement sensitivity of short and longer health status instruments. Med Care 1992;30:917-925.
38. Creange A, Serre I, Levasseur M, et al. Walking capacities in multiple sclerosis measured by global positioning system odometer. Mult Scler 2007;13:220-223.